Sebia’s Post

During the 2024 #AACR Annual Meeting this week, the concept of #metastasis has dramatically changed since its last plenary session 14 years ago.... David Lyden's session on "Evolution of the Genome, Microenvironment, and Host through Metastasis" reveals new insights on the importance of tumor-secreted factors and extracellular vesicles (EVPs) which can have downstream effect on different organs and can contribute towards a systemic effect. As Lyden's team discovered, EVPs as a result of a pancreatic tumor can disrupt the liver's function, increase the side effects of chemotherapy and even increase the likelihood of metastases outside the liver. Said differently, “if you have cancer going to the lung, you can’t ignore that you have a fatty liver as well.” The evolving understanding of metastasis emphasizes the need for a more comprehensive approach to cancer research and treatment. To learn more about his work and conference insights, continue reading here: https://lnkd.in/g_XJB3ed #Pharmaceutical #Biotech #Diagnoses #Medicine #Clinical #Healthcare #Lifescience #CancerResearch #CancerTreatment #CancerCells #Oncology #MedicalResearch #Healthcare #CancerAwareness #CancerBiology #InnovationInMedicine #HealthcareIndustry #CancerPrevention #CancerScience #HealthScience #MedicalCommunity #CancerEducation

Very excited to see the data from our collaboration with Jacob Berchuck and the team Dana-Farber Cancer Institute presented at #ESMO24 “Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform” 👉 https://lnkd.in/eYKWZB4c There is already one approved “blockbuster” medicine targeting PSMA and there are at least 30 more in development. Knowing whether a patient is PSMA+ve (established using PET with a PSMA specific tracer) is a requirement to Rx the one approved medicine, and it’s likely to play an important role in the future given its inclusion in many ongoing trials. Having a blood test would make it so much easier to find all of the eligible patients in practice. And there’s more data to come, including data that examine the link between determination of tumor PSMA expression using our platform and treatment outcome (and how that compares to the link between PET for PSMA and treatment outcome). What makes the clinical potential of our platform stand out even more is our ability to reveal additional high impact drug targets from the same blood test, creating the opportunity to enable precision use of medicines in a truly minimally invasive and accessible way 🩸 #cancerresearch #prostatecancer #ESMO #healthcare #liquidbiopsy #epigenomics Precede Biosciences

We are officially launching our new Residual Acute Myeloid (RAM) Application, expanding our oncology portfolio to support measurable residual disease (#MRD) capabilities. Our new solution will help monitor cancer and stay ahead of relapse, and it will be available to customers worldwide starting this July. Customers using the SOPHiA DDM TM RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. Our solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports. “AML (Acute Myeloid Leukemia) unfortunately still remains an area of high unmet medical need today, with associated suboptimal patient outcomes. MRD measurement and monitoring has a critical role to play, for example by enabling research into the most optimal sequencing of therapies,” said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. Learn more: https://loom.ly/yzYkk6Q #DataDrivenMedicine #Oncology #AML #SOPHiADDM

Humanized mouse models play crucial roles in oncology research. These advanced models offer effective strategies for evaluating potential therapies, including antibody-drug conjugates (ADCs) and bispecific antibody treatments, accelerating the development of innovative cancer therapies. You want to utilise humanized mice models for your research, we are only a message away. Fill out our inquiry form to hear back from our team and help you with advancing your research - https://gvrp.in/enquiry/ ................... GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform (GVRP) is an authorised distributor of Biocytogen humanized mice models in India. ................................. #researchmodels #preclinicalresearch #humanizedmicemodels #biomedicalresearch #advancedtools #precisiononcology #advancingtechnology #humanizedmouse

If you, or someone close to you, has been diagnosed with an advanced, incurable or poor prognosis cancer, at Omico, we are dedicated to help. We provide access at no cost to Comprehensive Genomic Profiling. This looks for changes in over 500 genes within your cancer cells to identify your cancer's "fingerprint", that is, the specific features that make up your cancer and what is driving it to grow. Knowing this information can help to identify any potential matches to precision treatments and clinical trials that are designed to target your unique cancer. We invite you to explore the information below to learn more about Omico, comprehensive genomic screening and the pathways to clinical trials and new, targeted treatments that it could potentially lead to. Watch our recent precision oncology information webinar for patients here: https://lnkd.in/gnj_S2Ff Please share it with your network and spread awareness on comprehensive genomic profiling and how it can help. #PatientWebinar #CancerMeetsItsMatch #Omico #PrecisionOncology #ComprehensiveGenomicProfiling

🌐 Real-World Data on #Immunotherapy Use in Early #NSCLC Pleased to share the real-world data on immunotherapy use in early-stage NSCLC presented by our team UAB O'Neal Comprehensive Cancer Center and collaborators at Flatiron Health at #WCLC24! 🧑🔬 Key findings: • Real-world insights on distant metastasis-free survival in early NSCLC patients 🚨 • Analysis of metastasis sites and the need for improved biomarker testing highlighted 🔄 Exciting work that underscores the importance of translating clinical research into everyday practice! #Immunotherapy #CancerCare #RealWorldEvidence #lcsm #NSCLC OncoAlert Bristol Myers Squibb AstraZeneca Merck Genentech

🚀 MSK-ACCESS® Powered by SOPHiA DDM™: Revolutionizing Liquid Biopsy Capabilities 🚀 Push the boundaries of liquid biopsy with MSK-ACCESS®, a decentralized version of the rigorously validated cfDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK) and powered by SOPHiA DDM™ SOPHiA GENETICS. This advanced technology offers unparalleled analytical performance for single nucleotide variants (SNVs), indels, copy number variants (CNVs), and fusions detection, across a comprehensive 146-gene panel curated by MSK experts. 💡 Why MSK-ACCESS®? 🔹 Matched tumor-normal approach: Minimize false positives with CHIP filtering, ensuring high specificity, especially at low allele frequencies. 🔹 End-to-end workflow: From cfDNA sampling to report generation in just ~5 days. 🔹 High analytical concordance: Achieves 99.4% positive agreement for variants at ≥0.5% VAF. 🔹 Maximized insights: Facilitates longitudinal monitoring for confident decision-making. Designed for research use, MSK-ACCESS® provides a comprehensive solution for precision oncology, enabling robust variant detection to guide treatment decisions and follow-up monitoring. Interested in taking your precision oncology program to the next level? Learn more by contacting us at: info@gen-era.com.tr 🔗 Read more: https://lnkd.in/epsv8JRq #PrecisionOncology #LiquidBiopsy #CancerGenomics #MSKACCESS #SOPHiADDM

𝗞𝗮𝗽𝗮𝗱𝗶 𝗮𝗻𝗱 𝗡𝗲𝘅𝘁 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝗮𝗺 𝗨𝗽 𝗳𝗼𝗿 𝗦𝗶𝘅 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 Exciting news! Next Oncology and Oncobay have joined forces to launch a series of groundbreaking Phase 1 clinical trials. Together, we are pushing the boundaries of cancer treatment! These trials will focus on evaluating novel immuno-oncology therapies designed to unleash the immune system's power against cancer. By combining our expertise, we aim to develop safer and more effective treatments for patients battling this relentless disease. Read the full press-release here: https://lnkd.in/dNhYazmU #CancerResearch #ImmunoOncology #ClinicalTrials #Collaboration #pressrelease #article #oncology #Kapadi #clinicaltrials #clinicalresearch #pharma #biotech

Exciting news! Our research on sensory ion channels in pancreatic cancer, published in the Journal of Personalized Medicine MDPI, has been selected as #Editor_Choice and is gaining traction of 3834 reads, 21 citations ! This work by Wenjie Shi et al. identifies potential targets for repurposing FDA-approved agents, offering promise for new treatment options. Read more here: https://lnkd.in/g32bMAmG #pancreaticcancer #medicalresearch #MESResearch

Thrilled to announce that the first patient has been dosed in our Phase 1/2 clinical study of REC-1245! REC-1245 is a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma. It also marks a significant milestone as the first program fully developed using the RecursionOS—our AI-powered platform that’s transforming drug discovery. Using our AI-driven Maps of Biology, we identified a novel target, discovered new chemical matter, and advanced REC-1245 from target identification to IND-enabling studies in under 18 months, synthesizing only ~200 compounds. This is an extraordinary achievement, much faster and more efficient than industry standards. “The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.” Read more: https://lnkd.in/ekidbGm8 #techbio #ai #clinicaltrial #cancer #oncology